HER2 testing in the UK: consensus from a national consultation.
about
Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridHER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimensEffect of patient age on management decisions in breast cancer: consensus from a national consultation.A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.Update on HER2 testing for breast and upper gastrointestinal tract cancers.HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.
P2860
HER2 testing in the UK: consensus from a national consultation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
HER2 testing in the UK: consensus from a national consultation.
@ast
HER2 testing in the UK: consensus from a national consultation.
@en
type
label
HER2 testing in the UK: consensus from a national consultation.
@ast
HER2 testing in the UK: consensus from a national consultation.
@en
prefLabel
HER2 testing in the UK: consensus from a national consultation.
@ast
HER2 testing in the UK: consensus from a national consultation.
@en
P2093
P2860
P356
P1476
HER2 testing in the UK: consensus from a national consultation.
@en
P2093
National HER2 Consultation Steering Group
P2860
P304
P356
10.1136/JCP.2006.044321
P407
P577
2007-02-23T00:00:00Z